- Despite Challenging Global Economic Conditions, Nucletron Surpassed Projections for the First Half Year
—
VEENENDAAL, the Netherlands, September 3VEENENDAAL, the Netherlands, September 3 /PRNewswire/ -- Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.
Net sales amounted to EUR 51.2 million, a 3% growth on like-for-like basis compared to the first half of 2008. EBITDA in the first half of 2009 amounted to EUR 6.3 million, a 53% increase compared to EUR 4.1 million over the same period last year. As a result of the positive developments Nucletron expects full year EBITDA to increase to EUR 19.0 million.
Jos Lamers, chief executive officer of Nucletron, comments: "Over the first six months of 2009, we have seen the results of our improved focus on innovation and our increased marketing efforts. Our senior management team is at full strength after the appointment of three new team members with a blue chip background. Combining our strength in marketing and sales with the research & development capabilities of Isodose Control will make Nucletron one of the global leaders in brachytherapy. Given our many upcoming product releases in the months ahead, we are on track to outperform our 2009 goals."
Among the several advancements made in the first half of 2009, Nucletron partnered with Advanced Radiation Therapy (ART) to offer a revolutionary solution for treating breast cancer. AccuBoost allows clinicians to use image-guidance, as used in a standard mammography, to pinpoint radiation directly to the tumour site. This allows for much better accuracy in targeting the radiation to the cancerous area, while protecting the patients' healthy organs during treatment.
The business collaboration with Isodose Control is now in place. The partnership allows clinicians to benefit from Nucletron's leadership and strength in brachytherapy with Isodose Control's track record of innovation.
Additionally, Nucletron launched its latest evolution in treatment planning for radiotherapy. Model-based segmentation in Oncentra MBS and volumetric modulated arc therapy with Oncentra VMAT ensure quality, while dramatically reducing the time needed to create treatment plans.
Visit our website http://www.nucletron.com
About Nucletron
Nucletron is a global leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians.
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
